Flamel Technologies (FLML) 9.99 $FLML
Flamel Technologies to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jun 01, 6:30AM CDT
LYON, FRANCE--(Marketwired - Jun 1, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences:
FLML: 9.99 (-0.38)
Flamel Technologies Reports First Quarter 2016 Results
Marketwire Canada - Mon May 09, 6:30AM CDT
Total Revenues of $36.2 Million; Adjusted Net Income of $1.6 Million and Adjusted Diluted EPS of $0.04; Adjusted EBITDA of $11.8 Million; Cash Flow From Operations of $22.5 Million
FLML: 9.99 (-0.38)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 244.90 (-5.56), ABT: 38.31 (-0.56), JNJ: 116.57 (-0.43), FLML: 9.99 (-0.38), IRWD: 12.82 (-0.18), GILD: 84.40 (-1.37), AMGN: 154.40 (-2.38), FGEN: 17.75 (-0.64), ENTA: 23.08 (-0.45), NVS: 78.86 (-1.65)
Flamel Technologies to Report First Quarter 2016 Results
Marketwired - Mon May 02, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 9.99 (-0.38)
Flamel Technologies Receives FDA Approval of Akovaz(TM)
Marketwired - Mon May 02, 6:30AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) for Akovaz(TM) (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL.
FLML: 9.99 (-0.38)
Flamel Technologies to Present at Upcoming Investor Conferences
Marketwired - Fri Apr 22, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences. Michael Anderson, Chief Executive Officer, and Mike Kanan, Chief Financial Officer, are scheduled to present at the following:
FLML: 9.99 (-0.38)
Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Marketwired - Thu Mar 31, 7:00AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the pivotal Phase III study of its once nightly Micropump(TM) based sodium oxybate product. The SPA will provide the FDA an opportunity to review and comment on the company's planned study design, and once accepted, offers general acknowledgement by the FDA that the trial's design, clinical endpoints and statistical analyses are acceptable and support the scientific and regulatory requirements associated with the product.
FLML: 9.99 (-0.38)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 9.99 (-0.38), VNDA: 10.87 (-0.11), GNCA: 4.02 (-0.20), DRRX: 1.35 (+0.03)
Why U.S. Steel, Flamel Technologies, and Sarepta Therapeutics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 10, 5:36PM CST
Image source: U.S. Steel. Thursday brought another day of relatively quiet trading on Wall Street, and major market benchmarks finished the day close to unchanged from Wednesday's levels. Investors were upbeat early in the day following a move from...
FLML: 9.99 (-0.38), SRPT: 20.07 (-0.92), X: 17.28 (-0.16)
Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results
Marketwired - Thu Mar 10, 7:01AM CST
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and full year of 2015.
FLML: 9.99 (-0.38)
Flamel Technologies to Present at the 28th Annual ROTH Conference
Marketwired - Tue Mar 08, 7:00AM CST
Flamel Technologies (NASDAQ: FLML) today announced that management will be presenting at the 28th Annual ROTH Conference to be held in Dana Point, California, March 13 - 16, 2016. Michael Anderson, Chief Executive Officer of Flamel, is scheduled to present on March 14th at 10:00 a.m. Pacific Time.
FLML: 9.99 (-0.38)
Flamel Technologies to Report Fourth Quarter and Full Year 2015 Results
Marketwired - Mon Mar 07, 3:05PM CST
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2015 on Thursday, March 10, 2016, before the market open. A conference call to discuss these results has been scheduled for Thursday, March 10, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 9.99 (-0.38)
57.3% Return Seen to Date on SmarTrend Flamel Technologies Call (FLML)
Comtex SmarTrend(R) - Thu Mar 03, 6:08PM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 5 months, Flamel Technologies has returned 57.26% as of today's recent price of $8.21.
FLML: 9.99 (-0.38)
Flamel Technologies Has Returned 51.0% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Wed Feb 10, 5:19PM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 5 months, Flamel Technologies has returned 51.02% as of today's recent price of $9.41.
FLML: 9.99 (-0.38)
Flamel Technologies Acquires FSC Pediatrics
Marketwired - Mon Feb 08, 3:01PM CST
Flamel Technologies (NASDAQ: FLML) today announced the acquisition of FSC Holdings, LLC, together with its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.. FSC is a Charlotte, NC-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients. Leveraging its 45 person sales force, FSC markets three pediatric pharmaceutical products indicated for infection, allergy, gastroesophageal disease (GERD), and a medical device for the administration of aerosolized medication using pressurized Metered Dose Inhalers (pMDIs) for the treatment of asthma. Prior to the acquisition, FSC was an affiliate of Deerfield CSF, LLC, a Deerfield Management company.
FLML: 9.99 (-0.38)
Shares of FLML Down 50.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 03, 10:32AM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 4 months, Flamel Technologies has returned 50.18% as of today's recent price of $9.57.
FLML: 9.99 (-0.38)
Flamel Technologies to Present at Two Upcoming Investor Conferences
Marketwired - Wed Jun 01, 6:30AM CDT
LYON, FRANCE--(Marketwired - Jun 1, 2016) - Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences:
FLML: 9.99 (-0.38)
Flamel Technologies Reports First Quarter 2016 Results
Marketwire Canada - Mon May 09, 6:30AM CDT
Total Revenues of $36.2 Million; Adjusted Net Income of $1.6 Million and Adjusted Diluted EPS of $0.04; Adjusted EBITDA of $11.8 Million; Cash Flow From Operations of $22.5 Million
FLML: 9.99 (-0.38)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 244.90 (-5.56), ABT: 38.31 (-0.56), JNJ: 116.57 (-0.43), FLML: 9.99 (-0.38), IRWD: 12.82 (-0.18), GILD: 84.40 (-1.37), AMGN: 154.40 (-2.38), FGEN: 17.75 (-0.64), ENTA: 23.08 (-0.45), NVS: 78.86 (-1.65)
Flamel Technologies to Report First Quarter 2016 Results
Marketwired - Mon May 02, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A conference call to discuss these results has been scheduled for Monday, May 9, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 9.99 (-0.38)
Flamel Technologies Receives FDA Approval of Akovaz(TM)
Marketwired - Mon May 02, 6:30AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) for Akovaz(TM) (ephedrine sulfate), a drug administered parenterally as a pressor agent to address clinically important hypotension in surgical settings. Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Flamel expects to launch Akovaz during the third quarter 2016 in a strength of 50 mg/mL.
FLML: 9.99 (-0.38)
Flamel Technologies to Present at Upcoming Investor Conferences
Marketwired - Fri Apr 22, 3:05PM CDT
Flamel Technologies (NASDAQ: FLML) today announced that management will present at two upcoming investor conferences. Michael Anderson, Chief Executive Officer, and Mike Kanan, Chief Financial Officer, are scheduled to present at the following:
FLML: 9.99 (-0.38)
Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
Marketwired - Thu Mar 31, 7:00AM CDT
Flamel Technologies (NASDAQ: FLML) today announced that it has filed a Special Protocol Assessment (SPA) with the U.S. Food and Drug Administration (FDA) for the pivotal Phase III study of its once nightly Micropump(TM) based sodium oxybate product. The SPA will provide the FDA an opportunity to review and comment on the company's planned study design, and once accepted, offers general acknowledgement by the FDA that the trial's design, clinical endpoints and statistical analyses are acceptable and support the scientific and regulatory requirements associated with the product.
FLML: 9.99 (-0.38)
Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions
ACCESSWIRE - Mon Mar 28, 7:01AM CDT
NEW YORK, NY / ACCESSWIRE / March 28, 2016 / DURECT Corporation (NASDAQ: DRRX), Genocea Biosciences Inc. (NASDAQ: GNCA), Flamel Technologies SA (NASDAQ: FLML), and Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) are four tickers in the biotech space currently suffering due to the overall poor market sentiment towards the space. The biotech sector has had a cruel start to the year. The Nasdaq Biotechnology Index is down 18% so far in 2016, and is now off about 30% since its July peak. This fall in market value has led to potential opportunities for big players in the space to pick up valuable assets are very low prices. While large drugmakers have hardly been exempt from the pain, the selloff should present a chance for them to find some cheap deals. Additionally, the four companies described here are expecting results from the FDA which may lead to even more upside for the junior biotech sector.
FLML: 9.99 (-0.38), VNDA: 10.87 (-0.11), GNCA: 4.02 (-0.20), DRRX: 1.35 (+0.03)
Why U.S. Steel, Flamel Technologies, and Sarepta Therapeutics Jumped Today
Dan Caplinger, The Motley Fool - Motley Fool - Thu Mar 10, 5:36PM CST
Image source: U.S. Steel. Thursday brought another day of relatively quiet trading on Wall Street, and major market benchmarks finished the day close to unchanged from Wednesday's levels. Investors were upbeat early in the day following a move from...
FLML: 9.99 (-0.38), SRPT: 20.07 (-0.92), X: 17.28 (-0.16)
Flamel Technologies Reports Fourth Quarter and Full Year 2015 Results
Marketwired - Thu Mar 10, 7:01AM CST
Flamel Technologies (NASDAQ: FLML) today announced its financial results for the fourth quarter and full year of 2015.
FLML: 9.99 (-0.38)
Flamel Technologies to Present at the 28th Annual ROTH Conference
Marketwired - Tue Mar 08, 7:00AM CST
Flamel Technologies (NASDAQ: FLML) today announced that management will be presenting at the 28th Annual ROTH Conference to be held in Dana Point, California, March 13 - 16, 2016. Michael Anderson, Chief Executive Officer of Flamel, is scheduled to present on March 14th at 10:00 a.m. Pacific Time.
FLML: 9.99 (-0.38)
Flamel Technologies to Report Fourth Quarter and Full Year 2015 Results
Marketwired - Mon Mar 07, 3:05PM CST
Flamel Technologies (NASDAQ: FLML) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2015 on Thursday, March 10, 2016, before the market open. A conference call to discuss these results has been scheduled for Thursday, March 10, 2016 at 10:00 a.m. ET. A question and answer period will follow management's prepared remarks.
FLML: 9.99 (-0.38)
57.3% Return Seen to Date on SmarTrend Flamel Technologies Call (FLML)
Comtex SmarTrend(R) - Thu Mar 03, 6:08PM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 5 months, Flamel Technologies has returned 57.26% as of today's recent price of $8.21.
FLML: 9.99 (-0.38)
Flamel Technologies Has Returned 51.0% Since SmarTrend Recommendation (FLML)
Comtex SmarTrend(R) - Wed Feb 10, 5:19PM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 5 months, Flamel Technologies has returned 51.02% as of today's recent price of $9.41.
FLML: 9.99 (-0.38)
Flamel Technologies Acquires FSC Pediatrics
Marketwired - Mon Feb 08, 3:01PM CST
Flamel Technologies (NASDAQ: FLML) today announced the acquisition of FSC Holdings, LLC, together with its wholly owned subsidiaries FSC Pediatrics, Inc., FSC Therapeutics, LLC, and FSC Laboratories, Inc.. FSC is a Charlotte, NC-based specialty pharmaceutical company dedicated to providing innovative solutions to unmet medical needs for pediatric patients. Leveraging its 45 person sales force, FSC markets three pediatric pharmaceutical products indicated for infection, allergy, gastroesophageal disease (GERD), and a medical device for the administration of aerosolized medication using pressurized Metered Dose Inhalers (pMDIs) for the treatment of asthma. Prior to the acquisition, FSC was an affiliate of Deerfield CSF, LLC, a Deerfield Management company.
FLML: 9.99 (-0.38)
Shares of FLML Down 50.2% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Feb 03, 10:32AM CST
SmarTrend identified a Downtrend for Flamel Technologies (NASDAQ:FLML) on September 24th, 2015 at $19.21. In approximately 4 months, Flamel Technologies has returned 50.18% as of today's recent price of $9.57.
FLML: 9.99 (-0.38)
